LIFE SCIENCE COMPASSIONATE ACCESS SUMMIT, PHILADELPHIA, MARCH 18-19, 2019
In today’s transparent clinical trial environment, HCP receive constant communication about trials and can offer an alternative treatment under expanded access, also known as compassionate use. Compassionate Access is a special exception made for the use of investigational drugs, biologics or medical devices used on patients during extenuating circumstances on an individual basis. As a life science organization and medical expert, it is your obligation to review fast and fairly to approve this request to send to regulators in the nation for regulators to ship the drug to the physicians. These responsibilities will ensure patient safety and expanded access capabilities, to execute a proper program that is compliant.
At ExL’s Life Science Compassionate Access Summit, attendees will be able to join industry leaders to explore compassionate use departments, compliance, market access, and understand the ethics of regulatory affairs to advance public health and widen the application within the life science industry.
Top Five Reasons to Attend
Who Should Attend
This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas: